Why innovator pharma companies should be pursuing biosimilars
This article was originally published in SRA
Executive Summary
Patent expiries, pricing pressures and the emergence of approval pathways in countries such as China and Brazil mean that biosimilars offer a substantial global opportunity, and there are many good reasons for originator companies to consider investing in this market segment, say Anna Buscall and Christopher Stothers.